Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 11/20 | 0.60 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30254794 | 0.95 | IL23R (0.61) | NPBWR1IL23R | |
| SCHEMBL29440486 | 0.93 | NPBWR1 (0.58) | NPBWR1GHSR | |
| SCHEMBL30636161 | 0.93 | NPBWR1 (0.58) | NPBWR1GHSR | |
| SCHEMBL29641119 | 0.92 | NPBWR1 (0.62) | NPBWR1GHSR | |
| SCHEMBL29461961 | 0.92 | NPBWR1 (0.62) | NPBWR1GHSR | |
| SCHEMBL29788453 | 0.91 | NPBWR1 (0.65) | NPBWR1IL23R | |
| SCHEMBL29641064 | 0.90 | NPBWR1 (0.66) | NPBWR1IL23RGHSR | |
| SCHEMBL30451792 | 0.90 | NPBWR1 (0.52) | NPBWR1OPRM1OPRD1GHSR | |
| SCHEMBL30464843 | 0.90 | MC4R (0.55) | OPRM1OPRD1 | |
| SCHEMBL30919247 | 0.89 | OPRD1 (0.57) | NPBWR1IL23ROPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | NPBWR1 4341/4885IL23R 4785/4885OPRM1 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.